AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36041227 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom burden assessment
Number of subjects: 45
Study 36041227 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of melphalan levels with dysgeusia
Number of subjects: 45
Study 36041227 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral microbiota assessment
Number of subjects: 45
Study 36041429 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine combined with apatinib and toripalimab (GAT)
Number of subjects: 41
Study 36041755 — intervention group
Group type: COMPARATOR
Intervention: Any antiarrhythmic therapies (AATs) including cardioversion, catheter ablation, and fulfilled antiarrhythmic drug (AAD) prescription.
Number of subjects: 239222
Study 36041755 — intervention group
Group type: COMPARATOR
Intervention: Any MHC (including depression, bipolar disorder, anxiety disorder, schizophrenia)
Number of subjects: 239222
Study 36041755 — intervention group
Group type: COMPARATOR
Intervention: AAD, cardioversion, and catheter ablation use
Number of subjects: 239222
Study 36041756 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-rated health (per 10-point increase)
Number of subjects: 574
Study 36041756 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-rated health
Number of subjects: 574
Study 36041981 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapered flow resistive loading
Number of subjects: 21
Study 36041981 — intervention group
Group type: COMPARATOR
Intervention: Pressure threshold loading
Number of subjects: 21
Study 36042020 — intervention group
Group type: EXPERIMENTAL
Intervention: dreaMS app tests
Number of subjects: 31
Study 36042076 — intervention group
Group type: EXPERIMENTAL
Intervention: VA primary care
Number of subjects: 1391
Study 36042076 — intervention group
Group type: EXPERIMENTAL
Intervention: VA mental healthcare
Number of subjects: 1391
Study 36042076 — intervention group
Group type: EXPERIMENTAL
Intervention: VA specialty care
Number of subjects: 1391
Study 36042076 — intervention group
Group type: EXPERIMENTAL
Intervention: Health issues
Number of subjects: 1391
Study 36042076 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental health issues
Number of subjects: 1391
Study 36042076 — intervention group
Group type: EXPERIMENTAL
Intervention: Military sexual trauma
Number of subjects: 1391
Study 36042076 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction with VA women's healthcare
Number of subjects: 1391
Study 36042229 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03 adjuvanted vaccination
Number of subjects: 0
Study 36042229 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59 adjuvanted vaccination
Number of subjects: 0
Study 36042229 — intervention group
Group type: COMPARATOR
Intervention: Control (no adjuvant)
Number of subjects: 0
Study 36042429 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling for active transportation (≥10 min/week)
Number of subjects: 671
Study 36042429 — intervention group
Group type: COMPARATOR
Intervention: Cycling for active transportation (<10 min/week)
Number of subjects: 671
Study 36042429 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking for active transportation (≥10 min/week)
Number of subjects: 671
Study 36042429 — intervention group
Group type: COMPARATOR
Intervention: Walking for active transportation (<10 min/week)
Number of subjects: 671
Study 36042472 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung cancer surgery (specific type not detailed)
Number of subjects: 620
Study 36042515 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA) measured by accelerometers over 15 days across three semesters (fall 2018, spring 2019, fall 2019)
Number of subjects: 4936
Study 36042515 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 4936
Study 36042527 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced hypertension treatment
Number of subjects: 34
Study 36042527 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (not specified)
Number of subjects: 34
Study 36042629 — intervention group
Group type: EXPERIMENTAL
Intervention: Clariscan (gadoterate meglumine)
Number of subjects: 766
Study 36042629 — intervention group
Group type: EXPERIMENTAL
Intervention: Other GBCAs (Dotarem®, Gadovist®, ProHance®)
Number of subjects: 766
Study 36042629 — intervention group
Group type: EXPERIMENTAL
Intervention: All GBCAs
Number of subjects: 766
Study 36043180 — intervention group
Group type: EXPERIMENTAL
Intervention: Regdanvimab 40 mg/kg
Number of subjects: 1315
Study 36043180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1315
Study 36043184 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 μg of SCB-2019 + CpG + aluminium hydroxide
Number of subjects: 0
Study 36043184 — intervention group
Group type: EXPERIMENTAL
Intervention: SCB-2019 formulations
Number of subjects: 0
Study 36043184 — intervention group
Group type: COMPARATOR
Intervention: ChAdOx1-S
Number of subjects: 0
Study 36043184 — intervention group
Group type: EXPERIMENTAL
Intervention: SCB-2019 or ChAdOx1-S
Number of subjects: 0
Study 36043326 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolute Onyx zotarolimus-eluting coronary stent
Number of subjects: 450
Study 36043326 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS/OCT-guided PCI
Number of subjects: 450
Study 36043728 — intervention group
Group type: EXPERIMENTAL
Intervention: French version of the Bath Ankylosing Spondylitis Functional Index (BASFI)
Number of subjects: 0
Study 36043728 — intervention group
Group type: EXPERIMENTAL
Intervention: French version of the Bath Ankylosing Spondylitis Global score (BAS-G)
Number of subjects: 0
Study 36044159 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound screening (US) of lower limbs 48 hours after admission and again after 5 days.
Number of subjects: 100
Study 36044159 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) ultrasound examination.
Number of subjects: 100
Study 36044159 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound screening (US) of lower limbs.
Number of subjects: 100
Study 36044258 — intervention group
Group type: EXPERIMENTAL
Intervention: Data-driven scoring model for balance rehabilitation exercises
Number of subjects: 19
Study 36044285 — intervention group
Group type: EXPERIMENTAL
Intervention: Unhealthy alcohol use (AUDIT-C ≥3 for women or ≥4 for men; PEth ≥50 ng/mL)
Number of subjects: 302
Study 36044285 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate alcohol use (AUDIT-C 1-2 for women or 1-3 for men; PEth 8 ≥ 50 ng/mL)
Number of subjects: 302
Study 36044285 — intervention group
Group type: COMPARATOR
Intervention: No alcohol consumption (self-report and PEth <8 ng/mL)
Number of subjects: 302
Study 36044385 — intervention group
Group type: EXPERIMENTAL
Intervention: Total metabolic tumor volume (TMTV) > 220 cm3 and performance status (PS) ≥ 2
Number of subjects: 301
Study 36044385 — intervention group
Group type: EXPERIMENTAL
Intervention: TMTV/Eastern Cooperative Oncology Group-PS combination
Number of subjects: 301
Study 36044388 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel plus pembrolizumab (200 mg every 21 days for up to 6 doses)
Number of subjects: 12
Study 36044388 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel plus pembrolizumab (given the day before tisagenlecleucel)
Number of subjects: 12
Study 36044388 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel plus pembrolizumab
Number of subjects: 12
Study 36044526 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (1,200 mg) plus Bevacizumab (7.5 mg/kg) administered every 3 weeks
Number of subjects: 43
Study 36044870 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide autogel (LAN) 120 mg every 28 days and temozolomide (TMZ) 250 mg/day for 5 consecutive days every 28-day cycle
Number of subjects: 40
Study 36045296 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-viral, specifically targeted CAR-T cells
Number of subjects: 0
Study 36045316 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid 500 mg three times daily
Number of subjects: 30
Study 36045434 — intervention group
Group type: EXPERIMENTAL
Intervention: Echelon Circular Powered (ECP) stapler
Number of subjects: 100
Study 36045434 — intervention group
Group type: COMPARATOR
Intervention: Manual Circular Staplers (MCS)
Number of subjects: 100
Study 36045453 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 373
Study 36045453 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 373
Study 36045453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 373
Study 36045513 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral brepocitinib
Number of subjects: 0
Study 36045710 — intervention group
Group type: EXPERIMENTAL
Intervention: EMPOWER information package
Number of subjects: 0
Study 36045710 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleepwell information package
Number of subjects: 0
Study 36045710 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 0
Study 36046132 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% milk, 3 cups/day for 3 months
Number of subjects: 73
Study 36046132 — intervention group
Group type: COMPARATOR
Intervention: Control group continued habitual intake of total dairy ≤ 1.5 servings/day (<1 cup of milk/day)
Number of subjects: 73
Study 36046132 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 73
Study 36046598 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO-149 OVD
Number of subjects: 36
Study 36046598 — intervention group
Group type: COMPARATOR
Intervention: HEC OVD
Number of subjects: 36
Study 36046613 — intervention group
Group type: EXPERIMENTAL
Intervention: Sick-day protocol administered via interactive voice response system (IVRS)
Number of subjects: 315
Study 36046613 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 315
Study 36046953 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low-energy diet (VLED) with sleeve gastrectomy (SG)
Number of subjects: 44
Study 36046953 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low-energy diet (VLED) with Roux-en-Y gastric bypass (RYGB)
Number of subjects: 44
Study 36046953 — intervention group
Group type: COMPARATOR
Intervention: Very low-energy diet (VLED) alone (control group)
Number of subjects: 44
Study 36047431 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional care combined with conventional care
Number of subjects: 368
Study 36047431 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 368
Study 36047494 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib
Number of subjects: 40
Study 36047494 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib with IFN-α
Number of subjects: 40
Study 36047494 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-α
Number of subjects: 40
Study 36047494 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib (in patients with pleural effusions)
Number of subjects: 40
Study 36047545 — intervention group
Group type: EXPERIMENTAL
Intervention: EVX-01 combined with pembrolizumab
Number of subjects: 0
Study 36047545 — intervention group
Group type: COMPARATOR
Intervention: Pembrolizumab alone
Number of subjects: 0
Study 36047604 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular burden (white matter hyperintensity [WMH] volumes)
Number of subjects: 120
Study 36047604 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediation analyses
Number of subjects: 120
Study 36047606 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported weight from mobile health app after 6 months
Number of subjects: 104
Study 36047606 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported weight from mobile health app after 12 months
Number of subjects: 104
Study 36047606 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrepancy in self-reported weight after 6 months based on baseline weight
Number of subjects: 104
Study 36047606 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrepancy in self-reported weight after 6 months based on BMI
Number of subjects: 104
Study 36047900 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing on vaginal self-samples using Evalyn Brush
Number of subjects: 486
Study 36047900 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing on vaginal self-samples using Qvintip
Number of subjects: 486
Study 36047900 — intervention group
Group type: COMPARATOR
Intervention: HPV testing on matched clinician-taken cervical samples
Number of subjects: 486
Study 36048266 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation durvalumab immune checkpoint inhibitor (ICI) therapy
Number of subjects: 39
Study 36048266 — intervention group
Group type: COMPARATOR
Intervention: Functional lung avoidance planning with chemoradiation
Number of subjects: 39
Study 36048266 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of COPD with perfused lung radiomics size features
Number of subjects: 39
Study 36048266 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of COPD with perfused lung radiomics shape features
Number of subjects: 39
Study 36048266 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfused lung radiomics size features
Number of subjects: 39
Study 36048362 — intervention group
Group type: EXPERIMENTAL
Intervention: ATMOS scoring system
Number of subjects: 59
Study 36048362 — intervention group
Group type: COMPARATOR
Intervention: Alvarado score
Number of subjects: 59
Study 36048362 — intervention group
Group type: COMPARATOR
Intervention: Tzanakis score
Number of subjects: 59
Study 36048535 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib in combination with buparlisib (BKM120)
Number of subjects: 0
Study 36048535 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant olaparib
Number of subjects: 0
Study 36048848 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care (KMC)
Number of subjects: 573
Study 36048877 — intervention group
Group type: EXPERIMENTAL
Intervention: Masitinib (30 μM)
Number of subjects: 0
Study 36048877 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled human liver microsomes with NADPH and potassium cyanide
Number of subjects: 0
Study 36048886 — intervention group
Group type: EXPERIMENTAL
Intervention: Children and adolescents diagnosed with mental disorders (intervention group)
Number of subjects: 150
Study 36048886 — intervention group
Group type: COMPARATOR
Intervention: Sex-matched children from the same postal area (control group)
Number of subjects: 150
Study 36048886 — intervention group
Group type: COMPARATOR
Intervention: Same parent siblings in the same household close in age +/- 3 years (control group)
Number of subjects: 150
Study 36048901 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-UART (July 2016-2020)
Number of subjects: 412
Study 36048901 — intervention group
Group type: COMPARATOR
Intervention: Pre-UART (2013-June 2016)
Number of subjects: 412
Study 36048901 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 412
Study 36048970 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide analogue (NA) therapy withdrawal
Number of subjects: 45
Study 36049283 — intervention group
Group type: EXPERIMENTAL
Intervention: BD Onclarity HPV Assay on first-void urine
Number of subjects: 492
Study 36049283 — intervention group
Group type: COMPARATOR
Intervention: Clinician-collected cervical samples
Number of subjects: 492
Study 36049381 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG monitoring during emergence from anesthesia
Number of subjects: 116
Study 36049381 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG features during emergence from anesthesia
Number of subjects: 116
Study 36049537 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-SWE (left lobe)
Number of subjects: 42
Study 36049537 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-SWE (right lobe)
Number of subjects: 42
Study 36049537 — intervention group
Group type: COMPARATOR
Intervention: VCTE
Number of subjects: 42
Study 36049654 — intervention group
Group type: EXPERIMENTAL
Intervention: Rezivertinib (BPI-7711) at 180 mg orally once daily until disease progression, unacceptable toxicity, or withdrawal of consent.
Number of subjects: 226
Study 36049817 — intervention group
Group type: EXPERIMENTAL
Intervention: Vericiguat
Number of subjects: 5050
Study 36049817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5050
Study 36050354 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous medium-frequency alternating electrical current stimulation at 2 kHz (PALS2)
Number of subjects: 25
Study 36050354 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous medium-frequency alternating electrical current stimulation at 2 kHz (3M2)
Number of subjects: 25
Study 36050354 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous medium-frequency alternating electrical current stimulation at 10 kHz (PALS10)
Number of subjects: 25
Study 36050354 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous medium-frequency alternating electrical current stimulation at 10 kHz (3M10)
Number of subjects: 25
Study 36050354 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 25
Study 36050354 — intervention group
Group type: EXPERIMENTAL
Intervention: 3M electrodes
Number of subjects: 25
Study 36050354 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous medium-frequency alternating electrical current stimulation at 2 kHz and 10 kHz
Number of subjects: 25
Study 36050567 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyaphron dispersion (PAD) technology
Number of subjects: 0
Study 36050656 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysis recovery time (DRT) assessment using patient-reported recovery duration post-dialysis.
Number of subjects: 191
Study 36050656 — intervention group
Group type: EXPERIMENTAL
Intervention: Malnutrition-Inflammation Score (MIS) assessment.
Number of subjects: 191
Study 36050656 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life assessment using KDQOL-36 questionnaire.
Number of subjects: 191
Study 36050656 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate sodium and number of missed sessions as predictors of DRT.
Number of subjects: 191
Study 36050661 — intervention group
Group type: EXPERIMENTAL
Intervention: pix2pix GAN synthesized images
Number of subjects: 708
Study 36050661 — intervention group
Group type: COMPARATOR
Intervention: Original images
Number of subjects: 708
Study 36050677 — intervention group
Group type: EXPERIMENTAL
Intervention: Equity-oriented intervention strategies implemented in EDs
Number of subjects: 4771
Study 36050677 — intervention group
Group type: EXPERIMENTAL
Intervention: Robust intervention activities at one ED site
Number of subjects: 4771
Study 36050677 — intervention group
Group type: COMPARATOR
Intervention: Control group (other ED sites with less robust intervention)
Number of subjects: 4771
Study 36050684 — intervention group
Group type: EXPERIMENTAL
Intervention: Health motive for meat reduction
Number of subjects: 25393
Study 36050684 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition motive for meat reduction
Number of subjects: 25393
Study 36050684 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical environment motive for meat reduction
Number of subjects: 25393
Study 36050684 — intervention group
Group type: EXPERIMENTAL
Intervention: Taste preferences for legume increase
Number of subjects: 25393
Study 36050684 — intervention group
Group type: EXPERIMENTAL
Intervention: Social influences, meat avoidance, and meat dislike
Number of subjects: 25393
Study 36050684 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific individual characteristics associated with change-inducing motives
Number of subjects: 25393
Study 36050723 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP device
Number of subjects: 41
Study 36050723 — intervention group
Group type: COMPARATOR
Intervention: ADx card
Number of subjects: 41
Study 36050737 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (CEUS)
Number of subjects: 50
Study 36050737 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of noradrenaline
Number of subjects: 50
Study 36050748 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with AKI
Number of subjects: 19
Study 36050748 — intervention group
Group type: COMPARATOR
Intervention: Patients without AKI
Number of subjects: 19
Study 36050800 — intervention group
Group type: EXPERIMENTAL
Intervention: C allele of rs3135506 in APOA5 (Women)
Number of subjects: 393
Study 36050800 — intervention group
Group type: EXPERIMENTAL
Intervention: C allele of rs429358 in APOE (Men)
Number of subjects: 393
Study 36050800 — intervention group
Group type: EXPERIMENTAL
Intervention: TT genotype of rs2854116 in APOC3
Number of subjects: 393
Study 36050800 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk alleles of APOA5 and APOE or APOC3 and APOE
Number of subjects: 393
Study 36050800 — intervention group
Group type: COMPARATOR
Intervention: SNPs in APOB (rs1042034) or LDLR (rs2228671)
Number of subjects: 393
Study 36050800 — intervention group
Group type: COMPARATOR
Intervention: Tested SNPs
Number of subjects: 393
Study 36050804 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative oral nutritional support (ONS)
Number of subjects: 318
Study 36050804 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ONS)
Number of subjects: 318
Study 36050896 — intervention group
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block (SGB) combined with prolonged exposure therapy (PE)
Number of subjects: 12
Study 36051040 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-dense immunochemotherapy with early systemic CNS prophylaxis
Number of subjects: 112
Study 36051045 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib 100 mg by mouth once daily in four-week cycles for up to 24 cycles
Number of subjects: 3
Study 36051466 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigil (gemogenovatucel-T)
Number of subjects: 0
Study 36051466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36051472 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Number of subjects: 0
Study 36051549 — intervention group
Group type: EXPERIMENTAL
Intervention: Everyday Life Rehabilitation (ELR) intervention
Number of subjects: 19
Study 36051549 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based training for staff
Number of subjects: 19
Study 36051549 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall perception of ELR
Number of subjects: 19
Study 36052222 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-ACLF patients (n=94)
Number of subjects: 1736